TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03831724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoFLIP™ System with FLIP Topography Module
Description: The EndoFLIP system with the EF-322N catheter will be used. The EndoFLIP system is a tool that assesses esophageal, esophago-gastric junction (EGJ)/lower esophageal sphincter (LES), and pylorus function. It allows the measurement of LES and pylorus distensibility as well as esophageal contractile activity in response to distension. The system uses impedance planimetry to measure luminal cross-sectional area (CSA) along an axial plane during volume-controlled distention.
Study: NCT02721888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinetic substudy (10 patients)
Study: NCT01044498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 8 mg/kg was administered in a single 1-hour infusion on Day 1 of Cycle 2.

Intervention type: DRUG
Group type: OTHER
Intervention: Ortho-Novum® 1/35
Description: Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho-Novum® 1/35
Description: Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.
Study: NCT04214015

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study: NCT00113139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based coping skills/stress management
Description: Telephone-based coping skills/stress management: 12 weekly sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care participants continued their routine and usual treatments and do not receive the 12 telephone training sessions.
Study: NCT02909426

Intervention type: DEVICE
Intervention: Ultrasonography
Description: Radiologists' hand-held bilateral breast ultrasonography for each participant for one time

Intervention type: DEVICE
Intervention: Digital mammography
Description: Full-field digital mammography using one of the equipments from General Electric (GE), Hologic, and Medi-future companies for each participant for one time
Study: NCT04251494

Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid intima media thickness measurement (CIMT)
Description: CIMT is a measurement of the thickness of the two inner layers of the common carotid artery wall. Using ultrasound, a linear array transducer is placed on the surface of the skin at the neck. Electrocardiogram(ECG) electrodes are placed on each wrist and one on the ankle. An image of the common carotid artery (CCA) is then produced in anterior, posterior and lateral views, and saved along with the ECG recording. The wall thickness can then be measured at the same point in the cardiac cycle using semi-automated detection software (Philips QLAB), which can reduce observer variability. The CIMT will be averaged across left and right CIMTs, as the control reference values use an average of both sides.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse Wave Velocity measurement
Description: The PWV measures the speed of a pulse wave travelling between two points in the vascular systems of known distance between them. PWV will be measured by the gold standard carotid-femoral PWV method which is a direct measurement of aortic stiffness. A 3-Lead ECG is connected alongside measurements of the blood velocity trace for the left CCA 2cm proximal to the bifurcation, and for the left common femoral artery origin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ankle-brachial pressure index (ABPI)
Description: A blood pressure cuff is placed around the ankle and upper arm of the participant. A continuous wave Doppler probe is used over the surface of the skin to locate the artery distal to the cuff (such as the brachial artery in the arm, or the anterior tibial and posterior tibial arteries in the ankle). The cuff is then inflated, and the systolic pressure identified by listening cessation of the sounds produced by the probe corresponding to blood flow in the artery. The ABPI is then the ratio of the highest systolic ankle pressure divided by the highest systolic brachial pressure for the left and right sides of the body.

Intervention type: OTHER
Intervention: Diet questionnaire and diet diary
Description: Dietary information will be collected in two formats. One will be a 14-item questionnaire (Martínez-González et al., 2012), which is a simplified version of a comprehensive food frequency questionnaire. This provides a quick measure of compliance to a Mediterranean dietary pattern and a rough measure of protective and adverse dietary factors that could affect individual CVD risk. The second will be a 3-day diet diary (3DDD). This will consist of participants recording the foods that they consume and the quantities, which will then be analysed for macro- and micronutrient composition once completed.
Study: NCT04384458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with 66 mg of zinc sulfate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Oral ivermectin dosage guidelines based on participant body weight, once on day for 2 consecutive days. This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.
Study: NCT03203668

Intervention type: RADIATION
Group type: OTHER
Intervention: 18F-choline PET/CT
Description: 18F-choline PET/CT imaging (neck, mediastinum)
Study: NCT03781739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MANP
Description: single subcutaneous injection of MANP and monitoring of metabolic, cardiovascular and renal parameters

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MANP
Description: single subcutaneous injection of MANP and monitoring of metabolic, cardiovascular and renal parameters
Study: NCT02534272

Intervention type: OTHER
Intervention: Stool sampling and sequencing of gut microbiota.
Study: NCT03198221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clenpiq
Description: bowel preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clenpiq
Description: bowel preparation
Study: NCT03650595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The TRANBERGCLS|Thermal Therapy
Description: MRI Guided Focal Laser Ablation of Prostate Cancer by The Diode Laser System - The TRANBERGCLS\|Thermal Therapy
Study: NCT03542448

Intervention type: DEVICE
Intervention: Swept source optical coherence tomography
Description: Measurement of choroidal thickness in myopic patients
Study: NCT01457300

Intervention type: OTHER
Intervention: Rehabilitation
Description: Model 1: Regular Assessment of Rehabilitation Goal, Rehabilitation Plan, Weekly Multi-Disciplinary Evaluation and Adjustment of Plan, Regular use of Measurement Scales, Regular Dialog between Personnel, Patient and Relatives. Model 2: More Occasional use of the Listed Activities. Model 1 and Model 2: Physical Training and Functional ADL Training, in Groups, One by One or Self-Training.
Study: NCT04724356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Intervention was led once per day, five days a week, over 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Intervention was led once per day, five days a week, over 8 weeks.
Study: NCT04432402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide: 10mg、15mg、20mg、25mg qd PO day 1-7, Rituximab: 375 mg/m2 IV day0, Gemcitabine :1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1 (every 14 days as a cycle)
Study: NCT03923218

Intervention type: OTHER
Intervention: LL-37 levels in Gingival crevicular fluid
Description: Collected gingival crevicular fluid

Intervention type: OTHER
Intervention: LL-37 levels in Gingival crevicular fluid
Description: Collected gingival crevicular fluid

Intervention type: OTHER
Intervention: LL-37 levels in Gingival crevicular fluid
Description: Collected gingival crevicular fluid

Intervention type: OTHER
Intervention: Serum Vitamin D3 levels
Description: Collected serum

Intervention type: OTHER
Intervention: Serum Vitamin D3 levels
Description: Collected serum

Intervention type: OTHER
Intervention: Serum Vitamin D3 levels
Description: Collected serum

Intervention type: OTHER
Intervention: Clinical parameters
Description: Recorded plague index, gingival index, probing depth, clinical attachment level

Intervention type: OTHER
Intervention: Clinical parameters
Description: Recorded plague index, gingival index, probing depth, clinical attachment level

Intervention type: OTHER
Intervention: Clinical parameters
Description: Recorded plague index, gingival index, probing depth, clinical attachment level
Study: NCT03937323

Intervention type: OTHER
Intervention: Blood lymphocyte subtypes and serum cytokines
Description: Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine the proinflammatory cytokines

Intervention type: OTHER
Intervention: Blood lymphocyte subtypes and serum cytokines
Description: Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine the proinflammatory cytokines
Study: NCT01605734

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: After obtaining arterial access,a diagnostic visceral arteriogram will be performed to demonstrate arterial supply to the tumor and the presence of variant arterial anatomy.After having positioned the catheter within the artery feeding tumor,the chemoembolization mixture will be infused into th e artery until stagnant flow is observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib combined with TACE
Description: All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
Study: NCT05231564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hybrid training
Description: The experimental group trained two to three sessions of 45 to 50 minutes a week with a recovery of 24 to 48 hours between each session to burn 500 kcal. The first three weeks held hybrid training with a metabolic program and the other three weeks held a strength training program.
Study: NCT02190760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study: NCT03841981

Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometric and physical examination
Description: * Weight and height.~* Waist-to-hip ratio.~* Body composition: Bioelectrical impedance and \[Dual energy X-ray absorptiometry (DEXA)\].

Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometric and physical examination
Description: * Weight and height.~* Waist-to-hip ratio.~* Body composition: Bioelectrical impedance and \[Dual energy X-ray absorptiometry (DEXA)\].

Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometric and physical examination
Description: * Weight and height.~* Waist-to-hip ratio.~* Body composition: Bioelectrical impedance and \[Dual energy X-ray absorptiometry (DEXA)\].

Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometric and physical examination
Description: * Weight and height.~* Waist-to-hip ratio.~* Body composition: Bioelectrical impedance and \[Dual energy X-ray absorptiometry (DEXA)\].

Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometric and physical examination
Description: * Weight and height.~* Waist-to-hip ratio.~* Body composition: Bioelectrical impedance and \[Dual energy X-ray absorptiometry (DEXA)\].

Intervention type: DIAGNOSTIC_TEST
Intervention: Indirect calorimetry, accelerometer and seven-day dietary recall
Description: Energy availability assessment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Indirect calorimetry, accelerometer and seven-day dietary recall
Description: Energy availability assessment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Indirect calorimetry, accelerometer and seven-day dietary recall
Description: Energy availability assessment.
Study: NCT02261857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized continuous positive airway pressure (CPAP) mask
Description: Personalized CPAP mask manufactured for study subjects using a combination of patient-specific computer-aided design and three-dimensional printing
Study: NCT01530880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Ibuprofen
Description: Ibuprofen 400 mg/100 mL intravenous (IV) over 30 minutes, followed by a continuous infusion of 2000 mg/500 mL at 85 mg/hour (21 mL/hour) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen (Standard of Care)
Description: Acetaminophen 650 mg via oral/nasogastric tube every 6 hours as needed for T\>=38.3 C (100.9 F) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first.
Study: NCT04444479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECG verification
Description: The correct positioning of the PICC catheter tip will be verified using ECG.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: X-ray verification
Description: The correct positioning of the PICC catheter tip will be verified using X-ray imaging.
Study: NCT04123769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydronidone
Description: First take Hydronidone capsule, single-dose and then Multiple-dose
Study: NCT00651586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% ophthalmic solution
Description: Gatifloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
Study: NCT02580734

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: Cross-over randomized clinical trials

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: melatonin
Description: Cross-over randomized clinical trials
Study: NCT00956826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Agit Vacuum
Description: With an electrode and a regular vacuum device
Study: NCT03122626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Together in Movement and Exercise (TIME) Program
Description: The TIME program is an evidence-based, standardized, progressive, licensed exercise program developed by physical therapists at the Toronto Rehabilitation Institute-University Health Network.
Study: NCT00112476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study: NCT05888025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Delivered Mindfulness-based Cognitive Therapy (MBCT-T)
Description: MBCT-T will be delivered in groups of four to eight subjects by telephone using a conference line with NYULH WebEx. Participants will receive a workbook containing session content and home practice logs and audio guides for home practice. Subjects will complete individual orientation sessions with the MBCT-T facilitator prior to start of the group sessions. The four subsequent weekly group sessions are approximately 90 minutes long. Participants will be encouraged to practice daily meditation in between group sessions for 20-30 minutes, six days per week
Study: NCT05218811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation Assisted Partial Nephrectomy
Description: Cryoablation Assisted Partial Nephrectomy is monitored under Ultrasound guidance, A Cryoablation machine (FDA Approved Device) along with its Cryoprobes are used in the study The Cryoprobes are placed in close to the endophytic tumor margins. The tumor boundary area will undergo one freezing cycles. Tumor is excised after 5 minutes of freezing cycle. Thawing process is passive, renal defect repair is conducted during thawing process.
Study: NCT02779205

Intervention type: PROCEDURE
Group type: OTHER
Intervention: adipose tissue sample
Description: adipose tissue sample

Intervention type: PROCEDURE
Group type: OTHER
Intervention: adipose tissue sample
Description: adipose tissue sample
Study: NCT00812669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT02872103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-627
Description: F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles. TA chemotherapy treatments are part of standard-of-care and not the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: F-627
Description: F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles. TA chemotherapy treatments are part of standard-of-care and not the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection on Day 2 of the first TA chemotherapy cycle. TA chemotherapy treatments are part of standard-of-care and not the study.
Study: NCT03617926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X92001666
Description: the X92001666 product is a lotion to be applied on dry hair for 15 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RID shampoo
Description: Active Comparator: RID shampoo The RID shampoo is to be applied on dry the hair for 10 minutes and then rinsed out with water. the product is to be applied on Day 0 and repeated again on Day 7.
Study: NCT00651586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 0.3% ophthalmic solution
Description: Ciprofloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
Study: NCT02753959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intervention
Description: Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~* Electrical impedance tomography (EIT)~* EMGpara~* SpO2~* tcCO2~* Respiratory inductance plethysmography~* EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~* Manual techniques only~* MIE at low pressure (+30 to -30)~* MIE at high pressure (+60 to -60)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable Intervention
Description: Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~* Electrical impedance tomography (EIT)~* EMGpara~* SpO2~* tcCO2~* Respiratory inductance plethysmography~* EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~* Manual techniques only~* MIE at low pressure (+30 to -30)~* MIE at high pressure (+60 to -60)
Study: NCT05093491

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry and ultrasonography in stroke group
Description: Ultrasonographic measurements were performed of the bilateral diaphragm and abdominal muscle thickness and thickening ratio in the supine position in the stroke patient group. The spirometric evaluation was also performed

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry and ultrasonography in healthy group
Description: Ultrasonographic measurements were performed of dominant side diaphragm and abdominal muscle thickness and thickening ratio in the supine position in healthy individuals group. The spirometric evaluation was also performed
Study: NCT00747162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measure of muscle oxygenation
Description: The investigators will use an INVOS oxymeter for muscle oxygenation measure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin pigmentation determination
Description: The investigators will use a DermaSpectrometer to get a reading from subjects' skin color
Study: NCT02344732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1%, Neomycin Sulfate and Polymyxin B Sulfate topical eye drops four times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.1%, Neomycin Sulfate and Polymyxin B Sulfate topical eye drops four times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homatropine 2% eye drops thrice daily
Study: NCT01994187

Intervention type: PROCEDURE
Intervention: Carotid endarterectomy

Intervention type: PROCEDURE
Intervention: carotid angioplasty